Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | CASP1 | P29466 | 3/20 | 1.00 |
| ▸ | CASP7 | P55210 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.59 |
| ▸ | HPGD | P15428 | 7/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14478987 | 0.80 | MAPT (0.72) | MAPTKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL4658021 | 0.79 | LIMK1 (0.85) | MAPTKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL4202216 | 0.78 | LIMK1 (1.00) | MAPTKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6250225 | 0.75 | ADORA2A (1.00) | MAPTKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL4899003 | 0.74 | MEN1 (0.59) | MAPTKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL11478409 | 0.71 | KDM4E (0.60) | MAPTKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL4199055 | 0.69 | LIMK1 (0.83) | MAPTKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL5530179 | 0.68 | HSD17B10 (0.54) | MAPTKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6254165 | 0.68 | ADORA1 (1.00) | MAPTKDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL23009504 | 0.67 | LMNA (0.67) | MAPTKDM4EMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364057-A1 | BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364057-A1 | BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230136466-A1 | BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230136466-A1 | BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364057-A1 | BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF | TOP1, DNA2, TOP2A | MAPT 3260/4885KDM4E 2244/4885MEN1 4457/4885 |
| US-20230136466-A1 | BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF | TOP1, DNA2, TOP2A | MAPT 3260/4885KDM4E 2244/4885MEN1 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.